We've pushed it from, as Pierre said, the shapes of the human genes, with one company and then three, and now we have nine making an inhibitor of it, which is a proto-drug. That's pushing it a little further. In July there's the discussion at CIHR with the six pharma, pushing it even further.
You can imagine a world where all this discovery stuff is done in the open, pre-competitively, and pharma competes much later, when the risk isn't whether it will work. The risk is a business risk—i.e., whether I can make a better medicine than my competitor.
That will change the whole economics of drug discovery, and should drop—